Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 5/20 | 0.48 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514212 | 0.93 | BACE1 (0.49) | ENPEPBACE1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31369342 | 0.93 | ENPEP (0.53) | ENPEPBACE1F2 | |
| SCHEMBL10375379 | 0.91 | ENPEP (0.54) | ENPEPBACE1F2 | |
| SCHEMBL10375374 | 0.91 | ENPEP (0.54) | ENPEPBACE1F2 | |
| SCHEMBL10374382 | 0.90 | ENPEP (0.53) | ENPEPBACE1F2 | |
| SCHEMBL10374381 | 0.90 | ENPEP (0.53) | ENPEPBACE1F2 | |
| SCHEMBL30627971 | 0.90 | FOLH1 (0.50) | BACE1 | |
| SCHEMBL31369290 | 0.89 | ENPEP (0.46) | ENPEPBACE1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30047082 | 0.89 | ENPEP (0.56) | ENPEPBACE1 | |
| SCHEMBL827833 | 0.88 | NMT2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388650-A1 | OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF | ENOSI THERAPEUTICS CORP (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024186690-A2 | OLIGO-TRAP FUSION PROTEINS (OFPS) AND USES THEREOF | ENOSI THERAPEUTICS CORPORATION (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-116847887-A | Methods and compositions for treating autoimmune diseases and cancers | 伊诺西治疗公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023168426-A1 | COMPOSITIONS AND CELLS CONTAINING MIXTURES OF OLIGO-TRAP FUSION PROTEINS (OFPS) AND USES THEREOF | ENOSI THERAPEUTICS CORPORATION (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4204094-A1 | METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER | ENOSI THERAPEUTICS CORPORATION (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220288226-A1 | METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER | ENOSI THERAPEUTICS CORPORATION | 2022-09-15 | — | — | US | disclosed |
| WO-2022047243-A1 | METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER | ENOSI LIFE SCIENCES CORP. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388650-A1 | OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF | TNFSF11, TNFRSF9, FCER2 | ENPEP 177/4885BACE1 3817/4885GRIN2D 4348/4885 |
| US-20220288226-A1 | METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER | TNFRSF1A, TNFRSF9, CD40 | ENPEP 2144/4885BACE1 4312/4885GRIN2D 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.